Dr Berwyn Clarke, CSO and Founder of Lab21 participated in the HGC seminar on October 25th to address diagnostic innovation and discuss fair and equitable frameworks for IP and diagnostic testing. Key findings and recommendations from the report include:
- UK research councils and other major biomedical research funders should review their guidelines on licensing of patents
- There is a need to establish a biomarker IP monitoring function within the Department of Health or appropriate cross-department office
- More support is needed for senior management in the NHS at a national level to develop the capacity to manage biomarker IP issues
- Generation of more independent evidence is required on the impact of biomarker IP on diagnostic innovation Commenting on the findings, Dr Clarke said: “In recent years, the area of personalised medicine and molecular diagnostics has greatly expanded. Respect for IP and complying with the regulatory framework for IVD clinical testing is critical in supporting investment and encouraging the development of high-class diagnostics in the UK market.”
The HGC seminar on IP and DNA diagnosis included expertise from Dr Clarke; Dr Michael Hopkins, Research Fellow of Science and Technology Policy Research at the University of Sussex; Dr Stuart Hogarth, Research Fellow at the Department of Political Economy at King’s College London; Dr Gail Norbury, Consultant Clinical Scientist and Commissioning and Governance Director at Genetics Laboratories; Dr M J Finley Austin, Scientific Liaison Officer at Roche; and Hadleigh Stollar, Programme Manager for the NHS Technology Adoption Centre.
For more information, please visit: www.hgc.gov.uk
For further information:
Lab21
Berwyn Clarke, CSO
t: +44 (0)1223 395461
e: Berwyn.clarke@lab21.com
For media and investor enquiries:
College Hill
Nicole Yost/Gemma Howe
t: +44 (0)20 7457 2020
e: lab21@collegehill.com
About Lab21
Lab21 is a global leader in personalised healthcare. It provides diagnostic products and services and supports blood bank screening, medical diagnostics and drug discovery. Lab21 customers include international healthcare providers, pharmaceutical and diagnostic companies. The Products division of Lab21 manufactures immunodiagnostic kits and reagents that are distributed internationally and is focused on infectious diseases for the blood-banking and clinical markets. Our clinical services operations has a growing test portfolio providing companion diagnostics and high technology molecular assays. Lab21's corporate offices are based in Cambridge, UK and South Carolina, with a GMP manufacturing site in Cambridge and other manufacturing facilities in Newmarket, Camberley and Bridport. The Company's investors include Excalibur, Nexus Medical Partners and Medicis Capital.
Website: www.lab21.com
